ACS Omega· 2026Q1· Review
Advances in Cubosome-Based Transdermal Delivery: Structural Design, Manufacturing, and Engineering Strategies
- 0citations
- Q1SCImago
- 2026year
Short summary
Cubosomes, lipidic nanocarriers with bicontinuous cubic structures, show promise for transdermal drug delivery due to their high surface area and ability to encapsulate diverse compounds.
AI-generated from the title and abstract; the full text is not read.
Key points
- Cubosomes are lipidic nanocarriers with bicontinuous cubic structures, enabling encapsulation of various drug types.
- Their nanostructure promotes interaction with the stratum corneum for transdermal delivery.
- Limitations include high viscosity, burst release, and inadequate deep dermal penetration.
- Advanced strategies like hybrid systems, surface functionalization, and stimuli-responsive designs address these limitations.
- Emerging technologies like microfluidics and AI are highlighted for next-generation cubosome development.
AI-generated from the title and abstract; the full text is not read.
Abstract
Abstract Cubosomes are third-generation lipidic nanocarriers characterized by bicontinuous cubic liquid-crystalline nanostructures and exceptionally high internal surface areas. These architectures enable the encapsulation of hydrophilic, hydrophobic, and amphiphilic compounds while providing enhanced stability, cargo protection, and controlled drug release. Their ordered nanostructure, governed by lipid self-assembly and critical packing parameter principles, promotes an effective interaction with the stratum corneum, making cubosomes promising transdermal delivery platforms. This review summarizes the physicochemical principles, fabrication technologies, and engineering strategies underlying cubosome-based transdermal systems. Specific crystallographic mesophases are influenced by lipid composition, stabilizers, guest molecules, and fabrication conditions, which determine the structural integrity and delivery performance. Despite their advantages, conventional cubosomes still exhibit limitations, including high bulk viscosity, burst release, inadequate deep dermal penetration, phase instability, and limited long-term stability. To overcome these challenges, advanced approaches including chemical phase modulation, hybrid integration with microneedles or hydrogels, surface functionalization, and stimuli-responsive systems are discussed. Emerging technologies such as microfluidics, quality by design, process analytical technology, artificial intelligence/machine learning-assisted optimization, and smart personalized transdermal drug delivery systems are also highlighted for next-generation cubosome development. These integrated strategies improve skin permeation, formulation stability, therapeutic efficacy, and manufacturing scalability while supporting the future translational development of cubosome-based nanomedicines for transdermal administration of small molecules and biomacromolecular therapeutics.
The authors' abstract, as published at the source. ACS Omega, 2026 · DOI ↗
The rest is in the Pofolia app
Takeaways and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openPharmaceutical SciencePharmacology, Toxicology and Pharmaceutics